Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

Last Friday saw the USA’s Center for Medicare and Medicaid Services (CMS) announce the selection of 15 new drugs covered ...

Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on KYMR stock, giving a Buy rating yesterday.Stay Ahead of the ...

Kymera Therapeutics, Inc. KYMR announced its business goals for 2025, along with anticipated progress on its pipeline of immunology programs. The stock rose 8% on the announcement. Shares of KYMR have ...

Kymera Therapeutics, Inc. has outlined its key objectives for 2025, emphasizing its strategy to advance a portfolio of oral ...

As for KT-621, the once-daily oral degrader of STAT6 protein is set to undergo a Phase 1b trial for atopic dermatitis (AD) in Q1, with data expected in Q4 2025. Phase 2b trials for KT-621 in AD ...

A statement from Gilead indicates that the deal is likely to lower its 2025 GAAP and non-GAAP earnings per share by $0.15 to ...

STAT6 is a transcription factor essential for IL-4 and IL-13 cytokine signalling, which are validated targets for Th2 mediated inflammatory conditions such as atopic dermatitis. Credit: ...